Myovant socks it to Orilissa
Two years after Abbvie’s disappointing launch of Orilissa Myovant hails the development of something much better.
New Genmab/Abbvie tie-up rings old bells
Followers of Nordic Nanovector and Oxford Biomedica, among others, will pay close attention to an early focus of yesterday’s deal.
UCB’s growth driver squares up against the competition
With data from a head-to-head trial against Cosentyx due soon, UCB’s bimekizumab seeks to enter a crowded psoriasis market.
Genmab brings on Abbvie for bispecific boost
Abbvie pays handsomely to join the CD20 bispecific brawl, handing over $750m to Genmab for access to a project that trails the competition.
Chinook marks an ignominious end for Sting
Aduro finally runs up the white flag on Sting agonism, and becomes a listed shell for Chinook Therapeutics.
US FDA approval tracker: several early decisions in May
Last month the FDA greenlit four oncology approvals early and the first GnRH antagonist in uterine fibroids.
Go or no go? A busy month ahead for US FDA decisions
June will be hectic for the US regulator, with many approval decisions due, including one for subcutaneous Arzerra in multiple sclerosis and Tazverik in follicular…
Galapagos finds little comfort in safety
Filgotinib’s mixed efficacy in ulcerative colitis prompts a shares slide.
J&J holds its own on sales per employee
Johnson & Johnson is easily the largest big pharma employer, and on certain metrics outstrips smaller rivals.
